Research reveals practice patterns in precision oncology

A new study of a cohort of Veterans Health Affairs (VHA) oncology patients illustrates complexity of clinician decision making around targeted therapies in a fast-moving field

Eliminating bias in health data science

It’s time for a renewed commitment to fairness, transparency and equity in data, big data and the algorithms for statistical or artificial intelligence (AI) models

Q&A: Interoperability and COVID-19, Part 2

Dr. Anil Jain describes how the pandemic’s disruption may affect the trajectory of sharing health information and considerations for those healthcare providers looking to invest.

A call for more complete race and ethnicity health data for COVID-19 response

Reported race and ethnicity health data is incomplete, with only 40 out of 50 states including this ...

Q&A: Interoperability and COVID-19, Part 1

How the pandemic response intersects with interoperability and requires healthcare providers to decide if they will defer or double-down on interoperability efforts.

How Long Will a Vaccine Really Take?

A vaccine would be the ultimate weapon against the coronavirus and the best route back to normal life.

The need to flatten the 4 curves of COVID-19

Responding to the pandemic requires us to “flatten the curve” that traces the physical impact of the disease. That's just the first curve. Additional curves are ascending for chronic disease management, mental health and economic health.

The search for life sciences solutions to the COVID-19 crisis

Helping to accelerate CROs that are working tirelessly and providing value to the clinical trial ...

Reimagine clinical trials with open approaches and interoperability

Read about our open technology philosophy and how it could increase patient engagement.

COVID-19 highlights the value of AI in helping to support patient care

The pandemic is pressing health systems to re-think how to use technology, such as artificial ...

The future of clinical trials is now

Given the enormous investment that the life sciences industry makes in drug development and the regulatory complexity of the work, it is not surprising that the adoption of novel approaches has been slow.

The untapped potential of real-world data for life sciences

As life sciences technologies progress, there’s a need to make room for changes in approach like new data resources. Real-world data (RWD) has the potential to transform the development and commercialization of new therapeutics.